PHASE 1-BMS-906024 by Bristol-Myers Squibb to treat breast, lung, and colon cancers and leukemia

New Drug Approvals

BMS-906024 is in Phase I clinical trials, both alone and in combination with other agents. Patients with colon, lung, breast, and other cancers are receiving intravenous doses of the compound to determine its safety and optimum dose ranges

New Phase I drug structure by Bristol-Myers Squibb disclosed at the spring 2013American Chemical Society meeting in New Orleans to treat breast, lung, and colon cancers and leukemia.^[1] The drug works as an pan-Notch inhibitor. The structure is one of a set patented in 2012,^[2] and it currently being studied in clinical trials.^[3][4]

 

1. C. Drahl, Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA, 2013, http://cenblog.org/the-haystack/2013/04/liveblogging-first-time-disclosures-of-drug-structures-from-acsnola/
2.  http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012129353
3.  http://clinicaltrials.gov/show/NCT01653470
4.  http://clinicaltrials.gov/show/NCT01292655

View original post